AR084932A1 - Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica - Google Patents
Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenicaInfo
- Publication number
- AR084932A1 AR084932A1 ARP120100268A ARP120100268A AR084932A1 AR 084932 A1 AR084932 A1 AR 084932A1 AR P120100268 A ARP120100268 A AR P120100268A AR P120100268 A ARP120100268 A AR P120100268A AR 084932 A1 AR084932 A1 AR 084932A1
- Authority
- AR
- Argentina
- Prior art keywords
- androgen
- treatment
- manufacture
- eye disease
- composition including
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Alternative & Traditional Medicine (AREA)
- Anesthesiology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Composiciones que comprenden una cantidad fisiológicamente efectiva de un andrógeno, en donde la composición es adecuada para la administración tópica a un ojo para el tratamiento de una enfermedad ocular. Uso de la composición para la fabricación de un medicamento útil para el tratamiento de una enfermedad ocular que resulta de una deficiencia de andrógenos.Reivindicación 3: La composición de la reivindicación 1, caracterizada porque el andrógeno es la testosterona.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161436274P | 2011-01-26 | 2011-01-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR084932A1 true AR084932A1 (es) | 2013-07-10 |
Family
ID=45567134
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120100268A AR084932A1 (es) | 2011-01-26 | 2012-01-26 | Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica |
Country Status (25)
Country | Link |
---|---|
US (8) | US9119772B2 (es) |
EP (2) | EP3388066B1 (es) |
JP (1) | JP6008876B2 (es) |
KR (1) | KR101914940B1 (es) |
CN (2) | CN109700763A (es) |
AR (1) | AR084932A1 (es) |
AU (4) | AU2012209184B2 (es) |
BR (1) | BR112013019257B1 (es) |
CA (1) | CA2825396C (es) |
CL (1) | CL2013002134A1 (es) |
DK (1) | DK2667877T3 (es) |
ES (1) | ES2672238T3 (es) |
HU (1) | HUE037660T2 (es) |
IL (1) | IL227573A (es) |
MX (1) | MX344046B (es) |
MY (1) | MY175318A (es) |
NO (1) | NO2667877T3 (es) |
PL (1) | PL2667877T3 (es) |
RU (1) | RU2599036C2 (es) |
SG (1) | SG192114A1 (es) |
TR (1) | TR201807857T4 (es) |
TW (1) | TWI593412B (es) |
UA (1) | UA114705C2 (es) |
WO (1) | WO2012103186A2 (es) |
ZA (1) | ZA201305812B (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
HUE037660T2 (hu) | 2011-01-26 | 2018-09-28 | Allergan Inc | Androgén készítmény szembetegség kezelésére |
WO2013181339A2 (en) | 2012-06-01 | 2013-12-05 | Allergan, Inc. | Cyclosporin a analogs |
EP2968365A1 (en) | 2013-03-15 | 2016-01-20 | Malhotra, Raman | Systemic administration of androgen in treating dry eye syndrome |
RU2592370C9 (ru) * | 2014-04-24 | 2016-08-27 | Иван Иванович Дедов | Средство на основе дегидроэпиандростерона, способ его применения |
TWI516281B (zh) * | 2014-07-16 | 2016-01-11 | 健維生技有限公司 | 改良之睪固酮製劑製法及所得之睪固酮製劑 |
US9463201B2 (en) | 2014-10-19 | 2016-10-11 | M.G. Therapeutics Ltd | Compositions and methods for the treatment of meibomian gland dysfunction |
WO2016112321A1 (en) | 2015-01-08 | 2016-07-14 | Allergan, Inc. | Cyclosporin derivatives wherein the mebmt sidechain has been cyclized |
IL257531B2 (en) * | 2015-09-17 | 2023-04-01 | Immunogen Inc | Medicinal compositions containing anti-folr1 immunoconjugates |
CN113144203A (zh) | 2015-09-28 | 2021-07-23 | 阿祖拉眼科有限公司 | 用于增加睑板腺脂质分泌物的含硫醇及二硫化物的药剂 |
EP3362096B1 (en) | 2015-10-14 | 2023-12-13 | Paul Gavaris | Ophthalmic treatment composition and vehicle for delivery of pharmaceutical substances or therapeutic agents |
BR112018070852B1 (pt) | 2016-04-14 | 2024-01-16 | Azura Ophthalmics Ltd | Composições de dissulfeto de selênio |
SG11201908454TA (en) * | 2017-02-17 | 2019-10-30 | Cempra Pharmaceuticals Inc | Triazole-containing macrolides and ophthalmic uses therefor |
KR20230079489A (ko) * | 2018-04-24 | 2023-06-07 | 알러간, 인코포레이티드 | 안구 증상의 치료를 위한 필로카르핀 염산염의 용도 |
WO2020069450A1 (en) * | 2018-09-28 | 2020-04-02 | Joel Studin | Transpore delivery of drugs and uses thereof |
US10744153B1 (en) * | 2019-07-01 | 2020-08-18 | Cloudbreak Therapeutics Llc | Compositions and methods for treating meibomian gland dysfunction |
CN115279458A (zh) | 2020-01-10 | 2022-11-01 | 阿祖拉眼科有限公司 | 组合物和敏感性说明 |
IL305451A (en) * | 2021-02-25 | 2023-10-01 | Alphyn Biologics Llc | A preparation for the treatment of local dermatological bacterial skin conditions |
US11746253B2 (en) * | 2021-03-08 | 2023-09-05 | Hoi Ming Michael HO | Sprayable conductive agent capable of forming conductive portion and manufacturing method and use thereof |
US11951123B2 (en) * | 2022-01-12 | 2024-04-09 | Platform Ophthalmic Innovations, LLC | Fortified nutritional lubricating drops for dry eye disease |
CN115105512A (zh) * | 2022-08-29 | 2022-09-27 | 中山大学中山眼科中心 | 脱氢表雄酮在制备预防、治疗眼部近视的药物中的用途及其剂型和制备方法 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2262182A (en) * | 1939-05-23 | 1941-11-11 | John V Huskamp | Closure valve for containers |
US3049003A (en) | 1956-09-05 | 1962-08-14 | Clark Equipment Co | Torque measurement apparatus |
DE3514724A1 (de) * | 1985-04-24 | 1986-10-30 | Albin F. Dr. 4200 Oberhausen Jereb | Salbe zur verbeugung und behandlung von augen- und hauterkrankungen |
US5364632A (en) | 1989-04-05 | 1994-11-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Medicinal emulsions |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US6093706A (en) * | 1992-03-04 | 2000-07-25 | Bioresponse, L.L.C. | Combined dehydroepiandrosterone and retinoid therapy for epithelial disorders |
AU674681B2 (en) | 1992-04-21 | 1997-01-09 | Schepens Eye Research Institute, Inc., The | Ocular androgen therapy in Sjogren's syndrome |
US6107289A (en) * | 1992-04-21 | 2000-08-22 | The Schepens Eye Research Institute, Inc. | Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β |
US5688765A (en) * | 1992-04-21 | 1997-11-18 | The Schepens Eye Research Institute, Inc. | Ocular therapy in Sjogren's syndrome using topically applied androgensor TGF-β |
US5958912A (en) * | 1992-04-21 | 1999-09-28 | The Schepens Eye Research Institute, Inc. | Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β |
JPH08507884A (ja) * | 1993-03-12 | 1996-08-20 | アラーガン、インコーポレイテッド | フェロモン添加剤を含有するアイケア用品およびその使用方法 |
US5474979A (en) | 1994-05-17 | 1995-12-12 | Allergan, Inc. | Nonirritating emulsions for sensitive tissue |
US6114319A (en) | 1997-05-14 | 2000-09-05 | Senju Pharmaceutical Co., Ltd. | Compositions containing difluprednate |
CA2294031E (en) * | 1997-07-29 | 2012-04-03 | Pharmacia & Upjohn Company | Self-emulsifying formulation for lipophilic compounds |
US5981607A (en) * | 1998-01-20 | 1999-11-09 | Allergan | Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers |
RU2246296C2 (ru) * | 1999-04-01 | 2005-02-20 | Акцо Нобель Н.В. | Композиция, включающая ундеканоат тестостерона и касторовое масло |
ES2242643T3 (es) * | 1999-11-09 | 2005-11-16 | Alcon Inc. | Sales de hidroxieicosatetraenoato, composiciones y metodos de uso en el tratamiento de trastornos del ojo seco. |
US20020009507A1 (en) * | 2000-01-19 | 2002-01-24 | Alcon Universal Ltd. | Use of polyethoxylated castor oil for the treatment of dry eye |
US20040214797A1 (en) * | 2001-05-07 | 2004-10-28 | Allergan, Inc. | Preserved pharmaceutical compositions comprising cyclodextrins |
US6872705B2 (en) * | 2001-07-13 | 2005-03-29 | Allergan, Inc. | Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions |
US20030109508A1 (en) * | 2001-10-11 | 2003-06-12 | Alcon, Inc. | Methods for treating dry eye |
US6659985B2 (en) * | 2002-01-30 | 2003-12-09 | Southern College Of Optometry | Method to use transdermal administration of androgens to the adnexa of the eye |
US6983600B1 (en) * | 2004-06-30 | 2006-01-10 | General Electric Company | Multi-venturi tube fuel injector for gas turbine combustors |
EP1655021B1 (en) | 2004-11-09 | 2008-10-29 | Novagali Pharma SA | Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential |
US20060210645A1 (en) * | 2005-03-02 | 2006-09-21 | Du Mee Charles P | Pharmaceutically acceptable carrier for ophthalmic compositions |
WO2006117910A1 (ja) | 2005-04-28 | 2006-11-09 | Mochida Pharmaceutical Co., Ltd. | 抗血小板膜糖蛋白質ⅵモノクローナル抗体 |
US8697152B2 (en) * | 2005-08-31 | 2014-04-15 | Johnson & Johnson Consumer Companies, Inc. | Anti-inflammatory compositions and personal care compositions comprising olive leaf (Olea europea) extract |
PL2581078T3 (pl) | 2005-10-26 | 2015-07-31 | Cydex Pharmaceuticals Inc | Kompozycje eteru sulfoalkilowego cyklodekstryny i sposoby ich wytwarzania |
US7629331B2 (en) | 2005-10-26 | 2009-12-08 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
US20070287983A1 (en) * | 2006-06-07 | 2007-12-13 | Richard Worthington Lodge | Absorbent article having an anchored core assembly |
US7390302B2 (en) | 2006-08-16 | 2008-06-24 | The General Electric Company | Method and system of determining NIBP target inflation pressure using an SpO2 plethysmograph signal |
US20080045486A1 (en) * | 2006-08-17 | 2008-02-21 | Tang-Liu Diane D S | Ocular administration of testosterone |
US20080132475A1 (en) * | 2006-12-05 | 2008-06-05 | Charles Gerald Connor | Treatment for dry eye |
US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
US20100305046A1 (en) * | 2009-06-02 | 2010-12-02 | Abbott Medical Optics Inc. | Stable cyclosporine containing ophthalmic emulsion for treating dry eyes |
HUE037660T2 (hu) | 2011-01-26 | 2018-09-28 | Allergan Inc | Androgén készítmény szembetegség kezelésére |
-
2012
- 2012-01-25 HU HUE12702934A patent/HUE037660T2/hu unknown
- 2012-01-25 JP JP2013551302A patent/JP6008876B2/ja not_active Expired - Fee Related
- 2012-01-25 ES ES12702934.6T patent/ES2672238T3/es active Active
- 2012-01-25 AU AU2012209184A patent/AU2012209184B2/en not_active Ceased
- 2012-01-25 DK DK12702934.6T patent/DK2667877T3/en active
- 2012-01-25 NO NO12702934A patent/NO2667877T3/no unknown
- 2012-01-25 RU RU2013138256/15A patent/RU2599036C2/ru active
- 2012-01-25 EP EP18160161.8A patent/EP3388066B1/en active Active
- 2012-01-25 PL PL12702934T patent/PL2667877T3/pl unknown
- 2012-01-25 EP EP12702934.6A patent/EP2667877B1/en active Active
- 2012-01-25 MX MX2013008528A patent/MX344046B/es active IP Right Grant
- 2012-01-25 MY MYPI2013002766A patent/MY175318A/en unknown
- 2012-01-25 UA UAA201310270A patent/UA114705C2/uk unknown
- 2012-01-25 TR TR2018/07857T patent/TR201807857T4/tr unknown
- 2012-01-25 CN CN201910213273.7A patent/CN109700763A/zh active Pending
- 2012-01-25 CA CA2825396A patent/CA2825396C/en not_active Expired - Fee Related
- 2012-01-25 KR KR1020137022364A patent/KR101914940B1/ko active IP Right Grant
- 2012-01-25 CN CN201280012140XA patent/CN103415292A/zh active Pending
- 2012-01-25 WO PCT/US2012/022508 patent/WO2012103186A2/en active Application Filing
- 2012-01-25 US US13/357,779 patent/US9119772B2/en active Active
- 2012-01-25 SG SG2013056379A patent/SG192114A1/en unknown
- 2012-01-25 BR BR112013019257A patent/BR112013019257B1/pt not_active IP Right Cessation
- 2012-01-26 AR ARP120100268A patent/AR084932A1/es not_active Application Discontinuation
- 2012-01-30 TW TW101102931A patent/TWI593412B/zh not_active IP Right Cessation
-
2013
- 2013-07-21 IL IL227573A patent/IL227573A/en active IP Right Grant
- 2013-07-25 CL CL2013002134A patent/CL2013002134A1/es unknown
- 2013-08-01 ZA ZA2013/05812A patent/ZA201305812B/en unknown
-
2014
- 2014-03-17 US US14/216,464 patent/US9937188B2/en active Active
-
2015
- 2015-08-31 US US14/840,276 patent/US9504646B2/en active Active
-
2016
- 2016-11-28 US US15/362,032 patent/US10905696B2/en active Active
-
2017
- 2017-09-14 AU AU2017228623A patent/AU2017228623A1/en not_active Abandoned
-
2018
- 2018-04-09 US US15/948,771 patent/US10780098B2/en active Active
-
2019
- 2019-04-10 AU AU2019202511A patent/AU2019202511A1/en not_active Abandoned
-
2020
- 2020-08-27 US US17/004,218 patent/US20210113588A1/en not_active Abandoned
- 2020-11-11 AU AU2020267198A patent/AU2020267198A1/en not_active Abandoned
-
2021
- 2021-01-12 US US17/147,176 patent/US20210268002A1/en active Pending
- 2021-11-12 US US17/454,746 patent/US20220202829A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR084932A1 (es) | Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica | |
PE20150092A1 (es) | Composiciones farmaceuticas que contienen fumarato de dimetilo | |
BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
EA201590053A1 (ru) | Модуляторы пути системы комплемента и их применение | |
EA201690102A1 (ru) | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе | |
AR090491A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo | |
HN2011002406A (es) | 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso | |
CU20130069A7 (es) | Derivados de 2,3-dihidroimidazo[1,2-c] quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermeddes asociadas a la angiogénesis | |
MY167691A (en) | A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid | |
UY31228A1 (es) | Ariloxazoles sustituidos y su uso | |
MX2015002239A (es) | Formulacion oftalmica de lipido polioxilo o de acido graso polioxilo y tratamiento de padecimientos oculares. | |
MX345042B (es) | Composiciones y métodos para tratamiento no quirúrgico de ptosis. | |
BR112015011430A2 (pt) | composição para liberação imediata e prolongada | |
CL2010001406A1 (es) | Composicion farmaceutica oftalmica que comprende povidona yodada, y un compuesto antiinflamatorio esteroidal, un compuesto antiinflamatorio no esteroidal, un antibacteriano, un antialergico o un compuesto antiglaucoma; y metodo para preservar la composicion. | |
BR112014010376A2 (pt) | medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima | |
MX367926B (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
DOP2012000284A (es) | Heterociclilbencilpirazoles sustituidos y uso de los mismos | |
MX2017004772A (es) | Composiciones y métodos para la administración fisiológica utilizando cannabidiol. | |
BR112014020271A8 (pt) | Composição farmacêutica e métodos para diminuir a frequência de micção em paciente | |
WO2014107730A3 (en) | Use of fatty acid niacin conjugates for treating diseases | |
GB2523707A (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
MY171048A (en) | Pharmaceutical composition for preventing or treating amyloid beta peptide-associated diseases or conditions | |
MX2016009217A (es) | Inmunoterapia basada en liposomas. | |
AR084197A1 (es) | Composicion para uso topico para el tratamiento de trastornos de la piel | |
CL2010001577A1 (es) | Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |